Home
Team
Technology
Investors
Stock Price
News
Financial Information
Analyst & Media Coverage
Presentations
R&D Papers
Clinical Papers & Abstracts
Conference Posters, Abstracts & Presentations
Corporate Governance
Pipeline
Contact Us
Phase I dose escalation study of immunoconjugate L-DOS47
Home
Phase I dose escalation study of immunoconjugate L-DOS47
02/06/2020
21/10/2023
admin
0 Comments
Conference presentations
Post navigation
Previous:
Helix BioPharma Corp. L-DOS47 Phase I Lung Cancer Trial Data to be released at ASCO 2020
Helix BioPharma Corp. to Present at Proactive One2One Virtual Investor Forum
:Next